Targeting inflammatory pathways for the treatment of cardiovascular disease (Q42410556)

30 October 2017

0 references

Targeting inflammatory pathways for the treatment of cardiovascular disease (English)

1 reference

30 October 2017

0 references

cardiovascular disease

1 reference

1

Paul M Ridker

1 reference

PMCID

3954097

30 October 2017

language of work or name

1 reference

7 November 2013

1 reference

30 October 2017

European Heart Journal

1 reference

30 October 2017

35

1 reference

30 October 2017

540-543

1 reference

30 October 2017

9

1 reference

Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis

30 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3954097

Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3954097

Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3954097

Evolution and emergence of therapeutic monoclonal antibodies: what cardiologists need to know

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3954097

Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3954097

C-reactive protein, fibrinogen, and cardiovascular disease prediction

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3954097

Non-invasive anatomic and functional imaging of vascular inflammation and unstable plaque

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3954097

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3954097

Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3954097

Treatment with methotrexate inhibits atherogenesis in cholesterol-fed rabbits

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3954097

Progress and challenges in translating the biology of atherosclerosis

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3954097

NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3954097

Interleukin-1-receptor antagonist in type 2 diabetes mellitus

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3954097

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3954097

Low-dose colchicine for secondary prevention of cardiovascular disease

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3954097

Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3954097

Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)

16 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24204011

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/EURHEARTJ/EHT398

1 reference

30 October 2017

1 reference

30 October 2017

1 reference

PMCID

3954097